These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19874860)

  • 1. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.
    Henriksen-Lacey M; Bramwell VW; Christensen D; Agger EM; Andersen P; Perrie Y
    J Control Release; 2010 Mar; 142(2):180-6. PubMed ID: 19874860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
    Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
    Henriksen-Lacey M; Devitt A; Perrie Y
    J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
    Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
    Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
    Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
    J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Dec; 164(3):331-7. PubMed ID: 22800572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
    Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
    Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying.
    Christensen D; Foged C; Rosenkrands I; Nielsen HM; Andersen P; Agger EM
    Biochim Biophys Acta; 2007 Sep; 1768(9):2120-9. PubMed ID: 17555704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV.
    Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):370-377. PubMed ID: 30691310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.
    Nordly P; Korsholm KS; Pedersen EA; Khilji TS; Franzyk H; Jorgensen L; Nielsen HM; Agger EM; Foged C
    Eur J Pharm Biopharm; 2011 Jan; 77(1):89-98. PubMed ID: 20940050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
    Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
    Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
    Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
    Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development.
    Mohammed AR; Bramwell VW; Kirby DJ; McNeil SE; Perrie Y
    Eur J Pharm Biopharm; 2010 Nov; 76(3):404-12. PubMed ID: 20884349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
    Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
    J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study.
    Kastner E; Hussain MJ; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2015 Mar; 67(3):450-63. PubMed ID: 25677402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.